INmune Bio Inc. has submitted a pre-submission package to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for CORDStrom™, a treatment for recessive dystrophic epidermolysis bullosa (RDEB). This pre-submission process is intended to obtain early feedback from the MHRA, which may help streamline the subsequent Marketing Authorization Application $(MAA)$ and potentially reduce the time required to bring the therapy to market. INmune Bio plans to file a full MAA with the MHRA following receipt of feedback, targeted for mid-summer 2026, with additional regulatory submissions in the EU and U.S. expected in the fourth quarter of 2026, pending regulatory alignment and manufacturing readiness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651612-en) on February 10, 2026, and is solely responsible for the information contained therein.